Recent Progress and Upcoming Paths: Current Developments in Chemotherapy for Metastatic Prostate Cancer Treatment
Niladri Shekhar Dey* and Rahul Kundu
ABSTRACT
Prostate cancer is the most frequently identified cancer in men and remains a major cause of cancer-related deaths. Precise and prompt diagnosis is crucial for differentiating clinically relevant tumours from non aggressive lesions and for guiding treatment choices. Multiparametric magnetic resonance imaging (mp MRI) has transformed prostate cancer detection through accurate lesion localization, risk assessment, and enhanced biopsy targeting. Fusion biopsy, integrating mp MRI results with real-time transrectal ultrasonography (TRUS), has become a highly efficient technique for sampling concerning lesions. Over the past thirty years, there have been swift advancements in the diagnosis and treatment of prostate cancer, such as multiparametric magnetic resonance imaging, positron emission tomography, robotic surgery, image-guided hypo fractionated and stereotactic radiotherapy, new anti-androgens, and radioligand therapies. This review addresses the current management of every stage of prostate cancer in view of recent advancements, allowing for comprehensive personalization of treatment, and highlights the potential of future studies to enhance results even further. In this document, we provide an extensive overview of the evidence backing the use of chemotherapy in the current management of advanced prostate cancer, focusing particularly on the application of chemotherapy for aggressive variant prostate cancer (such as neuroendocrine prostate cancer) and the integration of chemotherapy with androgen signalling inhibitors. As prostate cancer research advances quickly, producing new agents and treatment methods, chemotherapy remains vital for extending the lives of patients with advanced and metastatic prostate cancer.
